Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance

BACKGROUND: Nirmatrelvir-ritonavir (Paxlovid) and ensitrelvir are 3-chymotrypsin-like cysteine protease (3CL(pro)) inhibitors which have been approved for the treatment of COVID-19 in 2021 and 2022, respectively. Previous studies have identified 3CL(pro) mutations that are associated with reduced su...

Descripción completa

Detalles Bibliográficos
Autores principales: Ip, Jonathan Daniel, Wing-Ho Chu, Allen, Chan, Wan-Mui, Cheuk-Ying Leung, Rhoda, Umer Abdullah, Syed Muhammad, Sun, Yanni, Kai-Wang To, Kelvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101811/
https://www.ncbi.nlm.nih.gov/pubmed/37060743
http://dx.doi.org/10.1016/j.ebiom.2023.104559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101811/
https://www.ncbi.nlm.nih.gov/pubmed/37060743
http://dx.doi.org/10.1016/j.ebiom.2023.104559

Ejemplares similares